Diamond Hill Capital Management Inc. Trims Stake in Thermo Fisher Scientific Inc. $TMO

Diamond Hill Capital Management Inc. reduced its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 7.9% in the 4th quarter, Holdings Channel reports. The fund owned 460,301 shares of the medical research company’s stock after selling 39,639 shares during the period. Thermo Fisher Scientific makes up 1.4% of Diamond Hill Capital Management Inc.’s investment portfolio, making the stock its 27th largest position. Diamond Hill Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $266,721,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of the business. Brighton Jones LLC increased its position in shares of Thermo Fisher Scientific by 28.9% in the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares in the last quarter. Revolve Wealth Partners LLC increased its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares in the last quarter. Darwin Wealth Management LLC purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at approximately $170,000. Raymond James Financial Inc. increased its position in shares of Thermo Fisher Scientific by 7.4% in the second quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after buying an additional 53,542 shares in the last quarter. Finally, California State Teachers Retirement System increased its position in shares of Thermo Fisher Scientific by 0.4% in the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after buying an additional 2,262 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer directly owned 25,051 shares in the company, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of recent analyst reports. Citigroup boosted their price objective on Thermo Fisher Scientific from $660.00 to $685.00 and gave the company a “buy” rating in a research report on Friday, January 30th. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Barclays lowered their price target on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 14th. Royal Bank Of Canada set a $490.00 price target on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a research note on Thursday, May 14th. Finally, Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus target price of $616.10.

Thermo Fisher Scientific Stock Performance

Shares of NYSE:TMO opened at $449.43 on Friday. The business’s 50 day moving average price is $481.20 and its 200-day moving average price is $538.80. The firm has a market capitalization of $167.02 billion, a PE ratio of 24.71, a P/E/G ratio of 2.00 and a beta of 0.88. The company has a debt-to-equity ratio of 0.77, a current ratio of 1.53 and a quick ratio of 1.15. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, topping analysts’ consensus estimates of $5.25 by $0.19. The company had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, equities research analysts expect that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, July 15th. Shareholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 10.34%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.